Adalvo is excited to announce the launch of Pomalidomide Hard Capsules 1/2/3/4mg in Canada.
Our product is based on the reference brand, Pomalyst, and is indicated in the treatment of adult patients with multiple myeloma.
Pomalidomide Hard Capsules 1/2/3/4mghas been launched in collaboration with our strategic partner JAMP Pharma, a Canadian pharmaceutical group with over 35 years of experience. JAMP Pharma is committed to supporting healthcare professionals so that they may focus on what matters most: the well-being of patients.
This effective collaboration has allowed Adalvo to successfully implement a clearly defined IP pathway and provide the opportunity to be amongst the first wave of generic launches for this high-value, oncology product in Canada. This success story is a testament to the exceptional collaboration between Adalvo and JAMP Pharma.
Anil Okay, CEO of Adalvo, states,"This momentous achievement signifies Adalvo's commitment to delivering accessible and effective healthcare solutions towards the Oncology segment. By joining forces with JAMP Pharma, a trusted leader in the Canadian pharmaceutical industry, Adalvo are dedicated to making a meaningful difference in the lives of patients and further solidifying our position in the global market"
“We are delighted to introduce PrJAMP Pomalidomide in the Canadian market and therefore, solidify our leading position in the specialty market segment”, states Louis Pilon, CEO of JAMP Pharma Group. “Adalvo has been a keen collaborator in this new product launch, not only from a technical knowhow perspective, but also in sharing a common commitment to positively impact the lives of patients.”
About Adalvo
Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 100 countries and for over 110 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering highest quality differentiated products and services to our partners.
With headquarters in Malta, the company has additional offices in more than 16 countries. At Adalvo, we know that our partners like to be bigger, better, and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customized to our partners, and is designed to challenge the status quo: together, this helps our partners achieve their business goals.
We take pride in our ability to help partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities.
The company’s purpose driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.
About JAMP Pharma Group
JAMP Pharma Group is Canadian based with its head office located in the Montreal area. Having experienced exceptional growth over the past 10 years, JAMP Pharma Group is present in all segments of the pharmaceutical market with a portfolio of more than 315 molecules and is one of the leaders in the industry in terms of annual prescription volume*. In addition, with close to 40 new products authorized for sale by Health Canada in the last year, the JAMP Pharma Group is the Canadian leader in product launches**, enhancing the new treatment options available in Canada, including many specialty drugs. The Group also has its Swiss Wampole-Laboratory, Orimed Pharma and BIOJAMP brands, also offering 180 over-the-counter products with a diverse range of vitamins, supplements and natural products, as well as prescription and branded products and added value biosimilars products. The JAMP Care patient support program is designed to assist patients, as well as healthcare professionals, in taking specialty medications and biosimilars offered by the JAMP Pharma Group.
*Source: Pharmaceutical manufacturers with the highest volume of prescriptions reported in Canada between August 2018 and December 2022. Based in part on data obtained under license from IQVIA Solutions Canada, regarding the following service: CDH, MAT 2018/08 to 2022/12. All rights reserved. This statement is not necessarily that of IQVIA Solutions Canada Inc. or any of its affiliates or subsidiaries.
**Source: Pharmaceutical manufacturers with the highest volume of reported product launches in Canada between 2016 and 2021. Based in part on data obtained under license from IQVIA Solutions Canada, regarding the following service: CDH, MAT 2016/01 to 2021/12. All rights reserved. This statement is not necessarily that of IQVIA Solutions Canada Inc. or any of its affiliates or subsidiaries
Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.